| abstract |
The invention relates to biologically active molecules that bind to and inhibit thrombin. These molecules have a thrombin anion-binding exosate associate (aveam), a linker region of at least 18 a and a thrombin catalysed site directed portion (csdm). The invention also relates to compositions, combinations and methods utilizing these molecules for therapeutic, prophylactic and diagnostic purposes. |